How much does Enhertu (Trastuzumab Deruxtecan for Injection) Cost& price without insurance in China?
Enhertu® is the commercial brand name of Trastuzumab Deruxtecan for Injection, an antibody-drug conjugate jointly developed by Daiichi-Sankyo and AstraZeneca. It targets HER2 antigen on tumor cell surface to deliver cytotoxic payload into cancer cells and induce tumor cell death.
Main Indications
Treatment of unresectable or metastatic HER2-positive breast cancer after prior systemic therapies;
Treatment of unresectable or metastatic HER2-mutant non-small cell lung cancer.
Common Side Effects
Common mild adverse reactions: Nausea, fatigue, alopecia, vomiting and anemia.
Laboratory abnormalities: Decreased blood cell counts and transient liver enzyme elevation.
Severe but manageable risks: Interstitial lung disease, severe myelosuppression and infusion hypersensitivity reactions.
Approval Status in China
Enhertu® (Trastuzumab Deruxtecan for Injection, 100mg/vial) was officially approved for marketing in China in 2022. It is currently a prescription anti-tumor drug included in China’s Category B medical insurance.
Buy Enhertu (Trastuzumab Deruxtecan for Injection) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
